Table 2.
E2100
|
AVADO
|
RIBBON-1
|
|||||||||
---|---|---|---|---|---|---|---|---|---|---|---|
Adverse events [Grades 3 & 4] |
Paclitaxel only |
Paclitaxel + 10 beva |
Docetaxel + placebo |
Docetaxel + 7.5 beva |
Docetaxel + 15 beva |
Capecitabine + placebo |
Capecitabine + 15 beva |
Tax + placebo |
Tax + 15 beva |
Anthrac + placebo |
Anthrac + 15 beva |
Hypertension (%) | 0 | 14.8 | 1.3 | 0.8 | 4.5 | 1 | 10.1 | 2 | 8.9 | 0 | 10.5 |
Bleeding (%) | 0 | 0.5 | 0.9 | 1.2 | 0.8 | 0.5 | 0.2 | 0 | 5.4 | 0 | 1.0 |
Proteinuria (%) | 0 | 3.5 | 0 | 0.8 | 2 | 0 | 2.2 | 0 | 3.9 | 0 | 2.9 |
Neutropenia (%) | 0.3 | 0 | 17.3 | 19.8 | 19.8 | 1.0 | 1.2 | 4.9 | 9.4 | 4.0 | 4.3 |
Febrile neutropenia (%) | 0 | 0.8 | 11.3 | 15.1 | 16.2 | 0 | 0 | 2.0 | 8.4 | 5.0 | 3.8 |
Peripheral edema (%) | Not Provided | Not Provided | 2.6 | 1.2 | 0.4 | Not Provided | Not Provided | Not Provided | Not Provided | Not Provided | Not Provided |